◼ Archived
Business
New weight loss drug proves twice as powerful as Ozempic’s highest dosage
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Pharmaceuticals
122 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss
Eli Lilly reports that its new drug, retatrutide, achieved more than double the weight loss of Ozempic's highest approved dose in a head-to-head trial.
◼ Archived
Business
Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail
Novartis faces a multi-billion dollar financial hit from clinical trial setbacks yet maintains financial guidance.
◼ Archived
Business
Mo. Attorney General sends prescription manufacturer Eli Lilly cease-and-desist over drug price policy
Missouri's Attorney General issues a cease-and-desist letter to drug manufacturer Eli Lilly over a contested pricing policy.
◼ Archived
World
Roche’s changing plans show how MFN is complicating European drug launches
6 news sources are covering this World story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Exclusive | GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree
GSK anticipates its oncology clinical pipeline will nearly double in 2027 following an aggressive period of dealmaking and strategic acquisitions.
◼ Archived
Business
US judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo Nordisk
A US judge has ruled against Novo Nordisk, allowing Eli Lilly to continue running advertisements for its weight-loss medications.
◼ Archived
Business
Moderna’s Cancer Vaccine Rally Hits a Wall. This Other Drugmaker Stole the Show.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
The Most Powerful Obesity Drug Yet Has a Hidden Benefit—and It Happens While You Sleep
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Germany's Merck buys Silence Therapeutics in $1.3 billion RNA drug deal
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Roche returns to China’s Hansoh for $15B biobucks ADC pact
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
US: What We Have on Shkreli Is 'Just the Tip of the Iceberg'
Federal regulators and state authorities allege Martin Shkreli violated a lifetime pharmaceutical industry ban.
◼ Archived
Business
GLP-1 weight-loss drugs slow biological aging, recent studies show
Early research indicates GLP-1 weight-loss drugs may slow biological aging by up to four years, according to recent coverage.
◼ Archived
Health
GLP-1 drugs can ‘reverse biologic aging’ by two to three years, say drug companies
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
A simple daily pill could stop Parkinson's disease before it starts
A simple daily pill met its goals in a late-stage trial, raising prospects for halting Parkinson's disease before onset.
◼ Archived
Health
How GLP-1s are reshaping cultural views on body image
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Viatris to Buy Pacira BioSciences for $1.65 Billion
Viatris is expanding its innovative medicines strategy by acquiring Pacira BioSciences for $1.65 billion to lead in non-opioid pain therapies.
◼ Archived
Business
High cost of GLP-1s drives some to seek cheaper, unregulated versions
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
World
Pharmaceutical lobby sues Trump administration over most favored nation pricing
The pharmaceutical lobby group has launched a lawsuit against the Trump administration over most favored nation drug pricing policies.
◼ Archived
Business
CSL pays $355M to co-develop Alentis’ phase 2-stage fibrosis drug
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
New weight-loss drug could give you a ‘flatter stomach’ in mere weeks
1 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Novartis to License Drug From China’s Abogen in Up to $7.8 Billion Deal
Novartis strikes a massive licensing agreement worth up to $7.8 billion with China-based biotech firm Abogen.
◼ Archived
Business
America Wants to Make More Generic Drugs. India Shows Why That’s Hard.
The U.S. government is pushing to reshore the production of essential medicines amid new tariffs, while India's dominant role complicates these goals.
◼ Archived
Business
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
Sanofi and Regeneron have deepened their immunology alliance in a deal worth up to $8 billion to secure early-stage assets and a Dupixent successor.
◼ Archived
Business
Wall Street is closing out a strong quarter. Plus, Lilly's mixed obesity drug trial data
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Experimental Lilly combination drug tops Zepbound in weight-loss trial
An experimental combination drug from Eli Lilly outperforms Zepbound in a new weight-loss trial.
◼ Archived
Business
Most powerful obesity drug yet: People lost up to 25% of weight in trial
Eli Lilly's experimental triple agonist drug retatrutide demonstrates significant weight loss and A1C reduction in recent clinical trials.
◼ Archived
Business
Pharma's new top lobbyist is a former House majority leader
Eric Cantor, the former House majority leader, has been selected as the new president and chief executive officer of PhRMA.
◼ Archived
Business
Merck licenses a KRAS G12D inhibitor for $400M upfront
Merck has entered a multi-billion dollar agreement with China's SciBrunch Therapeutics to develop a preclinical KRAS G12D inhibitor.
◼ Archived
Health
Scientists are finally starting to figure out Alzheimer’s
Recent breakthroughs in immunology and new pharmaceutical frontiers are shifting the approach to treating Alzheimer's disease.
◼ Archived
Health
Is long-term use of GLP-1s safe?
Medical and lifestyle experts are questioning the long-term safety and efficacy of GLP-1 medications as they transition from clinical tools to consumer drugs.
◼ Archived
Health
Recall alert: 13K bottles of blood pressure medication recalled - WSB-TV
The FDA has issued a nationwide recall for over 13,000 bottles of Chlorthalidone blood pressure medication following failed dissolution testing.
◼ Archived
Business
Novartis secures new radioligand in $900M deal as competition strengthens
Novartis has expanded its portfolio by licensing a preclinical radioligand asset from BoomRay in a $900M transaction.
◼ Archived
Business
‘Boom, lights out’: Massachusetts man shares sudden blindness journey after taking GLP-1
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
Study finds possibly problematic drug combos being prescribed to older adults
A Canadian study warns that common drug combinations are triggering harmful prescribing cascades in older adults, risking their health and independence.
◼ Archived
Health
GLP-1 drugs dubbed ‘fountain of youth’ as doctors share surprising benefits beyond weight loss
GLP-1 medications face growing attention for unexpected health benefits and wider usage trends beyond weight management.
◼ Archived
Business
AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial
AstraZeneca's breast cancer pill Etcamah missed its primary goal in a late-stage trial, adding to oral SERD failures.
◼ Archived
Health
🔮 fades ✓
Inappropriate Prescribing Cascades Put Older Adults at Risk
Recent coverage examines inappropriate prescribing cascades where older adults receive new medications to treat side effects.
◼ Archived
Business
🔮 fades ✓
A Promising Heart Drug Failed. What Went So Wrong?
The failure of heart drug trials from pharmaceutical giants Novartis and Novo Nordisk creates a significant setback for a promising field of medicine.
◼ Archived
Business
🔮 fades ✓
Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes
Takeda Pharmaceutical's R&D chief Andy Plump is set to retire in June 2027 following a period of significant pipeline reorganization and regulatory success.
◼ Archived
Business
🔮 fades ✗
Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
A major Novartis shareholder is demanding a board overhaul following a series of costly drug trial setbacks and strategic failures.
◼ Archived
Business
🔮 fades ✓
Insilico's co-CEO hopes 'we might have a chance to stop biological aging'
Recent coverage explores potential links between a lung disease drug and the slowing of biological aging.
◼ Archived
Business
🔮 fades ✗
A New Drug Lifts the Fog of Sleepiness for Those With Narcolepsy
Takeda has released Phase 3 study data for oveporexton, a new drug designed to treat the excessive daytime sleepiness associated with narcolepsy.
◼ Archived
Business
🔮 fades ✓
How Novartis' Double-Stacked Failures Shook Biotech
Novartis is facing significant scrutiny within the biotech sector following a series of dual failures that have impacted investor confidence.
◼ Archived
Business
🔮 fades ✓
A breakthrough pancreatic cancer drug won approval. They still struggle to access it
A breakthrough pancreatic cancer drug wins FDA approval and hits the clinic, raising questions over patient access.
◼ Archived
Business
🔮 fades ✓
AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD
AstraZeneca reports positive Phase III trial results for tozorakimab, a drug targeting COPD exacerbations.
◼ Archived
Business
🔮 fades ✓
An AI-developed drug appeared to make patients biologically younger in a clinical trial
A clinical trial has indicated that a drug developed through artificial intelligence may have the capacity to make patients biologically younger.
◼ Archived
Health
🔮 holds ✗
Alzheimer’s treatment is advancing rapidly
Rapid advancements in medical research and a surge in clinical trials have positioned an Alzheimer's cure as a tangible possibility for the first time.
◼ Archived
Business
🔮 fades ✓
New drug shows promise in reducing COPD symptoms in former and current smokers, clinical trials show
AstraZeneca and Sanofi detail new respiratory clinical data at the #ERS26 conference.
◼ Archived
Business
🔮 fades ✗
Novartis Stock Tanks Following Third Major Pipeline Setback
Novartis stock experiences a sharp decline following a Phase 3 failure for a dystrophy drug linked to its $12 billion Avidity acquisition.
◼ Archived
Health
🔮 fades ✓
Drug developed for lung disease may slow biological aging in surprising ‘bonus’
A drug originally designed to treat lung disease may provide a surprising secondary benefit by slowing the process of biological aging.
◼ Archived
Business
🔮 fades ✓
Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test
Novartis shares experienced their worst single-day drop in over two decades following the failure of a crucial phase 3 trial for an Avidity buyout drug.
◼ Archived
Health
🔮 fades ✓
Study Suggests AI-Generated Drug Could Slow Aging
A new study suggests that a drug developed through artificial intelligence may have the potential to slow the biological process of aging.
◼ Archived
Business
🔮 fades ✗
Novo Nordisk Says Wegovy Shot Helped Children Lose Weight in Trial
Novo Nordisk's Wegovy shows weight-loss results in young children during trial data releases.
◼ Archived
Business
🔮 fades ✗
Novo scraps two more heart drug trials, further dimming growth beyond obesity
Novo Nordisk faces a diverging trajectory as it meets pediatric obesity goals but terminates two heart disease drug trials.
◼ Archived
Business
🔮 fades ✗
Novartis cholesterol setback tests hopes for emerging heart disease drugs
Novartis shares decline after its cholesterol drug pelacarsen failed a critical late-stage cardiovascular trial, impacting expectations for heart disease treatments.
◼ Archived
Business
🔮 fades ✓
Updated: Novo Nordisk cans 2 more trials of IL-6 heart drug for futility
Novo Nordisk has terminated two additional phase 3 trials of its cardiovascular drug ziltivekimab due to futility, impacting its growth strategy.
◼ Archived
Health
🔮 fades ✓
(Un)intended consequences of mass-prescribing GLP-1s
Recent reporting examines the widespread prescribing of GLP-1 medications and their broad societal and biological impacts.
◼ Archived
Health
🔮 fades ✗
Experimental weight loss jab outperforms Mounjaro in latest study
A new experimental weight loss injection has outperformed Mounjaro in a recent study, signaling a potential shift in obesity treatment.
◼ Archived
Business
🔮 fades ✗
Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials
Novartis shares climb following positive late-stage trial results for its experimental oral multiple sclerosis drug, Rhapsido.